These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24354863)

  • 1. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy.
    Baker DL; Peng K; Cheu M; Fischer SK
    Curr Med Res Opin; 2014 May; 30(5):913-22. PubMed ID: 24354863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.
    Kornmann O; Watz H; Fuhr R; Krug N; Erpenbeck VJ; Kaiser G
    Pulm Pharmacol Ther; 2014 Aug; 28(2):149-53. PubMed ID: 24657236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE.
    Lowe PJ; Georgiou P; Canvin J
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):68-77. PubMed ID: 25497995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
    Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
    Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab).
    Hamilton RG
    J Allergy Clin Immunol; 2006 Apr; 117(4):759-66. PubMed ID: 16630931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmapheresis prior to omalizumab administration in a 15-year-old boy with severe asthma and very high IgE levels: sustained effect over 2 years.
    Kerzel S; Zemlin M; Rogosch T; Ollert M; Renz H; Klaus G; Maier RF
    Klin Padiatr; 2011 Nov; 223(6):356-9. PubMed ID: 22012605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
    Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
    Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of assay for determining free IgE levels in serum from patients treated with omalizumab.
    Ito R; Gon Y; Nunomura S; Atsuta R; Harada N; Hattori T; Maruoka S; Okayama Y; Ra C; Hashimoto S
    Allergol Int; 2014 May; 63 Suppl 1():37-47. PubMed ID: 24809374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents.
    Steiss JO; Schmidt A; Nährlich L; Zimmer KP; Rudloff S
    Allergy Asthma Proc; 2012; 33(1):77-81. PubMed ID: 22370532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. Curr Med Res Opin 2014;30:913-22.
    Strohner P; Becher G
    Curr Med Res Opin; 2014 Oct; 30(10):1923-5. PubMed ID: 24914579
    [No Abstract]   [Full Text] [Related]  

  • 12. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
    Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
    J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22.
    Baker DL; Peng K; Cheu M; Fischer SK
    Curr Med Res Opin; 2014 Oct; 30(10):1927-9. PubMed ID: 24960148
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
    Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
    J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.
    Slavin RG; Ferioli C; Tannenbaum SJ; Martin C; Blogg M; Lowe PJ
    J Allergy Clin Immunol; 2009 Jan; 123(1):107-113.e3. PubMed ID: 19130931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of the total IgE level by omalizumab in children and adolescents.
    Steiss JO; Strohner P; Zimmer KP; Lindemann H
    J Asthma; 2008 Apr; 45(3):233-6. PubMed ID: 18415832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimisation of omalizumab dosage in patients with severe persistent allergic asthma using recoveryELISA.
    Steiß JO; Becher G
    BioDrugs; 2014 Oct; 28(5):445-50. PubMed ID: 24898594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma.
    Hochhaus G; Brookman L; Fox H; Johnson C; Matthews J; Ren S; Deniz Y
    Curr Med Res Opin; 2003; 19(6):491-8. PubMed ID: 14594521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Disease modification and duration of omalizumab treatment in patients with severe allergic asthma].
    Schreiber J; Kopp MV; Korn S; Taube C; Buhl R
    Pneumologie; 2014 Mar; 68(3):187-92. PubMed ID: 24477463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.